What We Do

Understanding, Treating and Monitoring Graft Health

Our Aim

To advance the outcomes of transplantation for patients by developing multidisciplinary approaches to understanding, treating and monitoring graft health.

We will do this by employing genetic technologies to:

Reduce the risk of graft rejection through better donor-patient matching;

Monitor the immune response after transplant to predict AMR

Enable personalized treatment with immunosuppressant drugs to prevent rejection while avoiding infection or cancer

Study the legal, ethical, societal and economic considerations of introducing these strategies into clinical practice to improve quality of life and reduce health-care costs

Ultimately, we are dedicated to increasing access to transplantation and achieving optimal clinical outcomes.

Activity 4

Activity 4: To Inform Health Policy Decisions through Social, Legal and Economic Data

We will use traditional methods of legal scholarship (e.g., the systematic and conceptual analysis of relevant case law, legislation, professional norms, legal theory, etc.) to assess how existing norms and obligations may play out when donor-recipient matching tools...
Activity 3

Activity 3: Personalizing Treatment Through Systems Pharmacology

Transplant medications have a very narrow therapeutic index (margin between efficacy and toxicity), so that under-treatment may allow rejection while over-treatment causes toxicity. Our research on quantitative pharmacokinetic methods monitoring ADME characteristics...
activity 2

Activity 2: Identifying Clinical Risk Through Immune Monitoring

Uremia is accompanied by profound disturbance of the immune response comprising both impaired immune defence and enhanced inflammation. We have shown that this complex picture is explained by profound perturbation of the human transcriptome mediated through the...
Activity 1: GCTC

Activity 1: Improving Donor Matching Through Epitope Typing

HLA matching at the epitope level offers new opportunities to identify compatible donors for kidney transplant candidates. It has been demonstrated that transplantation with significant epitope mismatches often result in the formation of new donor specific antibodies...